301 related articles for article (PubMed ID: 15650846)
1. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study.
Brook S; Walden J; Benattia I; Siu CO; Romano SJ
Psychopharmacology (Berl); 2005 Apr; 178(4):514-23. PubMed ID: 15650846
[TBL] [Abstract][Full Text] [Related]
2. The utility of intramuscular ziprasidone in the management of acute psychotic agitation.
Mendelowitz AJ
Ann Clin Psychiatry; 2004; 16(3):145-54. PubMed ID: 15517847
[TBL] [Abstract][Full Text] [Related]
3. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group.
Brook S; Lucey JV; Gunn KP
J Clin Psychiatry; 2000 Dec; 61(12):933-41. PubMed ID: 11206599
[TBL] [Abstract][Full Text] [Related]
4. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
Andrezina R; Josiassen RC; Marcus RN; Oren DA; Manos G; Stock E; Carson WH; Iwamoto T
Psychopharmacology (Berl); 2006 Oct; 188(3):281-92. PubMed ID: 16953381
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of ziprasidone versus haloperidol in sequential intramuscular/oral treatment of exacerbation of schizophrenia: economic subanalysis of the ZIMO trial.
Cañas F; Pérez-Solá V; Díaz S; Rejas J;
Clin Drug Investig; 2007; 27(9):633-45. PubMed ID: 17705572
[TBL] [Abstract][Full Text] [Related]
6. Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia.
Zhang H; Wang G; Zhao J; Xie S; Xu X; Shi J; Deng H; Li K; Gao C; Wang X; Vanderburg D; Pan S; Tang H; Shu L; Karayal ON
J Clin Psychopharmacol; 2013 Apr; 33(2):178-85. PubMed ID: 23422376
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
Daniel DG; Currier GW; Zimbroff DL; Allen MH; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
J Psychiatr Pract; 2007 May; 13(3):170-7. PubMed ID: 17522560
[TBL] [Abstract][Full Text] [Related]
8. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
Goff DC; Posever T; Herz L; Simmons J; Kletti N; Lapierre K; Wilner KD; Law CG; Ko GN
J Clin Psychopharmacol; 1998 Aug; 18(4):296-304. PubMed ID: 9690695
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
[TBL] [Abstract][Full Text] [Related]
10. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and tolerability of oral ziprasidone in psychiatric inpatients with an acute exacerbation of schizophrenia or schizoaffective disorder: a multicenter, prospective, and naturalistic study.
Díaz-Marsá M; Sánchez S; Rico-Villademoros F;
J Clin Psychiatry; 2009 Apr; 70(4):509-17. PubMed ID: 19358789
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON
Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
[TBL] [Abstract][Full Text] [Related]
13. Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia.
Brook S
J Clin Psychiatry; 2003; 64 Suppl 19():13-8. PubMed ID: 14728085
[TBL] [Abstract][Full Text] [Related]
14. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder.
Gunasekara NS; Spencer CM; Keating GM
CNS Drugs; 2002; 16(9):645-52. PubMed ID: 12153335
[TBL] [Abstract][Full Text] [Related]
16. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study.
Zimbroff D; Warrington L; Loebel A; Yang R; Siu C
Int Clin Psychopharmacol; 2007 Nov; 22(6):363-70. PubMed ID: 17917555
[TBL] [Abstract][Full Text] [Related]
17. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia.
Hirsch SR; Kissling W; Bäuml J; Power A; O'Connor R
J Clin Psychiatry; 2002 Jun; 63(6):516-23. PubMed ID: 12088164
[TBL] [Abstract][Full Text] [Related]
18. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.
Gunasekara NS; Spencer CM; Keating GM
Drugs; 2002; 62(8):1217-51. PubMed ID: 12010089
[TBL] [Abstract][Full Text] [Related]
19. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial.
Keck P; Buffenstein A; Ferguson J; Feighner J; Jaffe W; Harrigan EP; Morrissey MR
Psychopharmacology (Berl); 1998 Nov; 140(2):173-84. PubMed ID: 9860108
[TBL] [Abstract][Full Text] [Related]
20. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol.
Potkin SG; Weiden PJ; Loebel AD; Warrington LE; Watsky EJ; Siu CO
Int J Neuropsychopharmacol; 2009 Oct; 12(9):1233-48. PubMed ID: 19419595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]